X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-09-29 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.16 | -19,608 | 1,286,500 | -2% | -$101,091 | ||||||
2026-09-29 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $5.16 | -9,191 | 482,888 | -2% | -$47,385 | ||||||
2026-09-29 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $5.16 | -6,727 | 421,226 | -2% | -$34,682 | ||||||
2026-09-29 | ABEO | Abeona Therapeutics Inc. | Vasanthavada Madhav | Chief Commercial Officer | S - Sale | $5.16 | -4,902 | 285,721 | -2% | -$25,273 | ||||||
| D | 2026-09-28 | ADRX | Adarx Pharmaceuticals, Inc. | Sr One Capital Management, LLC | 10% | P - Purchase | $17.00 | +1,600,000 | 9,936,661 | +19% | +$27,200,000 | |||||
| D | 2026-09-28 | ADRX | Adarx Pharmaceuticals, Inc. | George Simeon | Dir, 10% | P - Purchase | $17.00 | +1,600,000 | 9,936,661 | +19% | +$27,200,000 | |||||
| D | 2026-09-28 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $13.53 | -13,400 | 69,828 | -16% | -$181,258 | |||||
2026-09-28 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $10.50 | -8,442 | 187,002 | -4% | -$88,618 | ||||||
| M | 2026-09-28 | KURA | Kura Oncology, Inc. | Ford Kathleen | COO | S - Sale | $10.59 | -10,574 | 142,986 | -7% | -$111,931 | |||||
| M | 2026-09-28 | KURA | Kura Oncology, Inc. | Leoni Mollie | Chief Medical Officer | S - Sale | $10.67 | -41,250 | 141,095 | -23% | -$440,237 | |||||
2026-09-28 | KURA | Kura Oncology, Inc. | Doyle Thomas James | SVP, Finance, Accounting | S - Sale | $10.50 | -4,607 | 142,928 | -3% | -$48,361 | ||||||
| M | 2026-09-28 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $10.63 | -32,450 | 136,819 | -19% | -$345,036 | |||||
2026-09-28 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.60 | +103,500 | 1,166,000 | +10% | +$889,872 | ||||||
2026-09-25 | MNOV | Medicinova Inc | 3D Investment Partners Pte. Ltd. | Formerly 10% Owner | S - Sale | $2.70 | -640,000 | 4,862,047 | -12% | -$1,728,000 | ||||||
2026-09-28 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $10.00 | -25,000 | 1,639,208 | -2% | -$250,000 | ||||||
| D | 2026-09-28 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $480.85 | -9,500 | 668,728 | -1% | -$4,568,106 | |||||
2026-09-10 | VRXA | Veraxa Biotech AG | Hosseinion Warren | Dir | P - Purchase | $1.67 | +6,024 | 634,692 | +1% | +$10,060 | ||||||
| A | 2026-09-22 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +10,100 | 9,424,556 | 0% | +$455 | |||||
| D | 2026-09-24 | MNPR | Monopar Therapeutics | Robinson Chandler | CEO | S - Sale+OE | $88.00 | -29,056 | 162,082 | -15% | -$2,556,851 | |||||
2026-09-25 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale | $3.29 | -39,051 | 713,258 | -5% | -$128,478 | ||||||
| D | 2026-09-28 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $65.46 | -7,500 | 282,710 | -3% | -$490,950 | |||||
| D | 2026-09-25 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $476.17 | -9,500 | 668,728 | -1% | -$4,523,635 | |||||
2026-09-28 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.06 | +3,400 | 9,429,956 | 0% | +$187 | ||||||
2026-09-24 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $2.78 | +7,000 | 672,000 | +1% | +$19,460 | ||||||
2026-09-24 | ANIX | Anixa Biosciences Inc | Baskies Arnold M | Dir | P - Purchase | $2.76 | +5,000 | 140,572 | +4% | +$13,800 | ||||||
2026-09-25 | DMRA | Damora Therapeutics, Inc. | Jarrett Jennifer | Dir, Pres, CEO | P - Purchase | $20.23 | +12,500 | 512,500 | +3% | +$252,875 | ||||||
| D | 2026-09-24 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $13.50 | -600 | 69,828 | -1% | -$8,103 | |||||
2026-09-23 | ADAG | Adagene Inc. | Tam Man Kin | CFO | P - Purchase | $3.00 | +2,000 | 37,000 | +6% | +$6,000 | ||||||
2026-09-25 | CYPH | Cypherpunk Technologies Inc. | Oei Khing Djien | Dir | S - Sale | $3.92 | -168,750 | 0 | -100% | -$661,500 | ||||||
2026-09-23 | CYPH | Cypherpunk Technologies Inc. | Martin Patricia A. | Dir | S - Sale | $3.86 | -50,000 | 118,750 | -30% | -$193,000 | ||||||
| D | 2026-09-24 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $473.55 | -9,500 | 668,728 | -1% | -$4,498,753 | |||||
2026-09-24 | ANNX | Annexon, Inc. | Love Douglas | Pres, CEO | P - Purchase | $3.83 | +26,065 | 390,476 | +7% | +$99,829 | ||||||
| D | 2026-09-24 | KURA | Kura Oncology, Inc. | Burrows Francis | Chief Scientific Officer | S - Sale+OE | $10.83 | -20,726 | 42,327 | -33% | -$224,514 | |||||
2026-09-24 | PHIO | Phio Pharmaceuticals Corp. | Bradford Patricia A | Dir | P - Purchase | $1.01 | +6,500 | 64,151 | +11% | +$6,583 | ||||||
| D | 2026-09-23 | PHVS | Pharvaris N.V. | Monges Viviane | Dir | S - Sale+OE | $33.05 | -11,969 | 5,500 | -69% | -$395,524 | |||||
2026-09-23 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $2.69 | +49,036 | 1,046,003 | +5% | +$131,907 | ||||||
2026-09-22 | MLYS | Mineralys Therapeutics, Inc. | Slingsby Brian Taylor | Dir | S - Sale | $28.81 | -104,320 | 7,805,718 | -1% | -$3,005,303 | ||||||
| DM | 2026-09-22 | OMER | Omeros Corp | Borges David J. | VP, Finance, CAO | S - Sale+OE | $20.95 | -20,000 | 0 | -100% | -$419,000 | |||||
2026-09-22 | TNGX | Tango Therapeutics, Inc. | Newcomb Jessica | Principal Accounting Officer | S - Sale | $24.22 | -8,200 | 59,121 | -12% | -$198,613 | ||||||
| M | 2026-09-22 | SKYE | Skye Bioscience, Inc. | Schwab Andrew J. | Dir, 10% | S - Sale | $1.62 | -148,079 | 981,269 | -13% | -$239,555 | |||||
| D | 2026-09-23 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $491.57 | -9,500 | 668,728 | -1% | -$4,669,918 | |||||
| M | 2026-09-22 | SKYE | Skye Bioscience, Inc. | 5Am Partners Vii, LLC | 10% | S - Sale | $1.62 | -148,079 | 981,269 | -13% | -$239,555 | |||||
2026-09-22 | RPRX | Royalty Pharma Plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $58.53 | -100,000 | 293,601 | -25% | -$5,853,095 | ||||||
2026-09-23 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $39.17 | -2,210 | 559,225 | 0% | -$86,565 | ||||||
| D | 2026-09-23 | AKTS | Aktis Oncology, Inc. | Czibere Akos | Chief Medical Officer | S - Sale+OE | $20.69 | -12,500 | 0 | -100% | -$258,621 | |||||
2026-09-22 | ANL | Adlai Nortye Group Ltd. | Ji Ping | Dir | S - Sale | $16.63 | -5,000 | 131,667 | -4% | -$83,150 | ||||||
| D | 2026-09-22 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Dir | S - Sale+OE | $36.19 | -800 | 115,167 | -1% | -$28,952 | |||||
2026-09-21 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $7.70 | -55 | 118,014 | 0% | -$424 | ||||||
| M | 2026-09-21 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.10 | +15,089 | 2,855,318 | +1% | +$31,687 | |||||
2026-09-21 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, EVP, Treasurer | S - Sale | $25.00 | -4,139 | 168,707 | -2% | -$103,475 | ||||||
2026-09-21 | OKUR | Onkure Therapeutics, Inc. | Saccomano Nicholas A | Pres, CEO | S - Sale | $2.97 | -87 | 11,160 | -1% | -$259 | ||||||
2026-09-21 | OKUR | Onkure Therapeutics, Inc. | Leverone Jason A. | CFO | S - Sale | $2.97 | -302 | 18,500 | -2% | -$898 | ||||||
| D | 2026-09-22 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $494.83 | -9,500 | 668,728 | -1% | -$4,700,851 | |||||
2026-09-21 | LEGN | Legend Biotech Corp | Santos Carlos E | CFO | S - Sale | $9.14 | -5,430 | 14,246 | -28% | -$49,630 | ||||||
2026-09-22 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $1.03 | +2,000 | 364,871 | +1% | +$2,058 | ||||||
2026-09-21 | PHVS | Pharvaris N.V. | Nassif David W. | CFO , CLO | S - Sale | $36.47 | -6,000 | 113,800 | -5% | -$218,801 | ||||||
| D | 2026-09-21 | MLYS | Mineralys Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale+OE | $28.12 | -7,438 | 38,400 | -16% | -$209,136 | |||||
| D | 2026-09-22 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $68.29 | -3,500 | 153,902 | -2% | -$239,015 | |||||
| D | 2026-09-18 | TEVA | Teva Pharmaceutical Industries Ltd | Savage Brian | Interim GC | S - Sale+OE | $38.85 | -7,342 | 8,500 | -46% | -$285,215 | |||||
2026-09-22 | BFRG | Bullfrog Ai Holdings, Inc. | Blacher Joshua | CFO | P - Purchase | $0.53 | +50,000 | 65,000 | +333% | +$26,425 | ||||||
2026-09-22 | BFRG | Bullfrog Ai Holdings, Inc. | Singh Vininder | CEO, 10% | P - Purchase | $0.60 | +75,000 | 2,442,446 | +3% | +$44,918 | ||||||
| D | 2026-09-21 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $494.56 | -9,500 | 668,728 | -1% | -$4,698,271 | |||||
2026-09-18 | TEVA | Teva Pharmaceutical Industries Ltd | Mignone Roberto | Dir | S - Sale | $39.06 | -367,600 | 119,807 | -75% | -$14,356,802 | ||||||
2026-09-22 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +10,100 | 1,056,800 | +1% | +$455 | ||||||
2026-09-17 | SION | Sionna Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $6.33 | -3,448,811 | 6,456,234 | -35% | -$21,835,018 | ||||||
2026-09-17 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $69.08 | -10,000 | 5,057,460 | 0% | -$690,847 | ||||||
| M | 2026-09-16 | BOLT | Bolt Biotherapeutics, Inc. | Yonehiro Grant | COO | S - Sale | $3.32 | -13,176 | 17,269 | -43% | -$43,807 | |||||
2026-06-05 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | SVP, Finance, PAO | P - Purchase | $3.88 | +509 | 17,082 | +3% | +$1,973 | ||||||
| M | 2026-09-16 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | SVP, Finance, PAO | S - Sale | $3.32 | -7,842 | 17,082 | -31% | -$26,072 | |||||
2026-06-05 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Pres, CEO, CFO | P - Purchase | $3.88 | +637 | 25,384 | +3% | +$2,469 | ||||||
| M | 2026-09-16 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Pres, CEO, CFO | S - Sale | $3.32 | -17,566 | 25,384 | -41% | -$58,402 | |||||
2026-09-21 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale | $95.75 | -533 | 14,219 | -4% | -$51,035 | ||||||
| D | 2026-09-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $50.35 | -6,018 | 38,000 | -14% | -$303,003 | |||||
| D | 2026-09-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | CHIEF MEDICAL OFFICER | S - Sale+OE | $50.35 | -5,000 | 25,000 | -17% | -$251,754 | |||||
| D | 2026-09-17 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale+OE | $29.37 | -31,599 | 69,956 | -31% | -$927,970 | |||||
2026-09-21 | CYBN | Cybin Inc. | Halstead Michael | CEO | P - Purchase | $13.47 | +100,000 | 168,568 | +146% | +$1,347,050 | ||||||
| D | 2026-09-21 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | GC | S - Sale+OE | $93.64 | -10,000 | 29,995 | -25% | -$936,417 | |||||
| D | 2026-09-18 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $494.79 | -9,500 | 668,728 | -1% | -$4,700,505 | |||||
2026-09-18 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.43 | +100,000 | 1,062,500 | +10% | +$843,460 | ||||||
| D | 2026-09-17 | PHVS | Pharvaris N.V. | Lu Peng | Pres | S - Sale+OE | $35.00 | -100,000 | 64,953 | -61% | -$3,500,000 | |||||
2026-09-17 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Dir | S - Sale | $35.00 | -200,000 | 115,167 | -63% | -$7,000,000 | ||||||
| D | 2026-09-18 | NBP | Novabridge Biosciences | Dennis Phillip Andrew | Chief Medical Officer | S - Sale+OE | $0.71 | -8,209 | 173,427 | -5% | -$5,828 | |||||
| D | 2026-09-17 | PHVS | Pharvaris N.V. | Bjork Elisabeth | Dir | S - Sale+OE | $37.89 | -52,500 | 15,167 | -78% | -$1,989,409 | |||||
| D | 2026-09-17 | PHVS | Pharvaris N.V. | Glassman Robert | Dir | S - Sale+OE | $38.56 | -14,493 | 10,500 | -58% | -$558,812 | |||||
2026-09-17 | PHVS | Pharvaris N.V. | Lesage Anne | Chief Early Development | S - Sale | $38.27 | -20,000 | 130,419 | -13% | -$765,466 | ||||||
2026-09-15 | NTHI | Neonc Technologies Holdings, Inc. | Garnett Keithly | CFO | S - Sale | $3.36 | -5,000 | 281,410 | -2% | -$16,809 | ||||||
2026-09-16 | CORT | Corcept Therapeutics Inc | Vieira Roberto Wandenkolk | Pres, Oncology | S - Sale | $100.82 | -296 | 3,946 | -7% | -$29,843 | ||||||
2026-09-16 | SKYE | Skye Bioscience, Inc. | Schwab Andrew J. | Dir, 10% | S - Sale | $1.91 | -33,892 | 1,129,348 | -3% | -$64,734 | ||||||
2026-09-16 | SKYE | Skye Bioscience, Inc. | 5Am Partners Vii, LLC | 10% | S - Sale | $1.91 | -33,892 | 1,129,348 | -3% | -$64,734 | ||||||
| M | 2026-09-16 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $67.49 | -20,000 | 1,459,860 | -1% | -$1,349,728 | |||||
| DM | 2026-09-16 | HRMY | Harmony Biosciences Holdings, Inc. | Budur Kumar | CHIEF MEDICAL OFFICER | S - Sale+OE | $43.05 | -38,452 | 13,115 | -75% | -$1,655,416 | |||||
| D | 2026-09-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $496.06 | -9,500 | 668,728 | -1% | -$4,712,580 | |||||
| D | 2026-09-17 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $497.54 | -8,300 | 45,172 | -16% | -$4,129,608 | |||||
| D | 2026-09-17 | DNTH | Dianthus Therapeutics, Inc. /De/ | Carr Edward | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $101.38 | -20,000 | 0 | -100% | -$2,027,646 | |||||
2026-09-16 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $25.00 | -3,674 | 112,508 | -3% | -$91,853 | ||||||
2026-09-16 | MPLT | Maplight Therapeutics, Inc. | Hanson Kristopher | GC | S - Sale | $11.67 | -16,509 | 137,044 | -11% | -$192,660 | ||||||
| D | 2026-09-16 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $16.33 | -12,394 | 39,900 | -24% | -$202,437 | |||||
| D | 2026-09-16 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $152.24 | -4,302 | 0 | -100% | -$654,923 | |||||
2026-09-16 | CBIO | Crescent Biopharma, Inc. | Lynch Ryan | See Remarks | S - Sale | $17.90 | -240 | 13,631 | -2% | -$4,296 | ||||||
2026-09-16 | CBIO | Crescent Biopharma, Inc. | Pinkas Jan | Chief Scientific Officer | S - Sale | $17.90 | -658 | 21,581 | -3% | -$11,778 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |